MASCO GROUP acquired by ARDIAN

Transcarent completed its acquisition of Accolade on April 8, 2025, following a definitive agreement announced on January 8, 2025. The transaction is structured as a full‑takeover, with Accolade ceasing to be a Nasdaq‑listed company and becoming a privately held subsidiary within the combined group. The strategic rationale is centered on the creation of a unified, AI‑driven “One Place for Health and Care” platform. Transcarent’s WayFinding experience, generative AI‑powered navigation, and complex‑care pathways in Cancer Care, Surgery Care, and Weight Health are combined with Accolade’s strengths in health advocacy, expert medical opinions (EMO), and virtual primary care. This integration allows members to access benefits navigation, clinical guidance, and end‑to‑end care delivery through a single interface, with the explicit goal of improving utilization patterns, lowering total care costs, and enhancing member experience for employers and payers. The combined organization now serves over 20 million members and more than 1,700 employer and health‑plan clients, creating a large‑scale, digitally‑native health services platform with significant optionality for cross‑selling, technology integration, and further ecosystem expansion.

Kersia is acquiring the animal biosecurity cleaners and disinfectants business from Neogen® through an exclusive agreement. This strategic transaction marks a major entry for the French group into the North American swine and poultry markets, complementing its existing domestic presence in the ruminant sector. The acquisition is a transformative step for the group, doubling its American activity and positioning it among the top three global players in the agricultural hygiene and disinfection market. The strategy focuses on leveraging the target's extensive product registration portfolio and its three dedicated U.S. manufacturing sites to provide nationwide coverage. This deal also expands the acquirer's international footprint into 20 new countries, particularly in Central America and the Asia-Pacific region, supporting its ambition to become the undisputed global leader in animal biosecurity.

21 Invest France acquired a majority stake in ProductLife Group from its founder who sought to institutionalize the company and secure resources for its next growth phase. The transaction was structured to allow the management team to reinvest significantly alongside 21 Invest. The strategic roadmap was focused on transforming PLG into an undisputed global leader through massive international consolidation.

Motion Equity Partners acquired a majority stake in Banook Group from Turenne Sante. The transaction was structured as a growth-oriented LBO, with the management team and Turenne Sante reinvesting substantially. The primary goal was to provide Banook with the resources to accelerate its buy-and-build strategy, focusing on North American expansion and diversification into eCOA and biostatistics.

Permira acquired Ergomed in a recommended cash offer, taking the company private from the London Stock Exchange (AIM). The transaction was driven by the thesis that Ergomed's next phase of growth—requiring significant investment in technology and international expansion (particularly in the US)—could be better executed away from the public markets. The deal structure allowed the founder, Miroslav Reljanović, to roll over a portion of his equity and remain involved, ensuring continuity. Strategically, Permira aims to supercharge Ergomed's "Site Management" model and its pharmacovigilance capabilities through both organic investment and accretive M&A.

Cerba HealthCare acquired the Canadian CRO Cirion BioPharma Research to integrate it into its global clinical trial business unit, Cerba Research. This move establishes a critical operational hub in North America, allowing the group to offer seamless cross-continental support for drug development programs. The transaction followed Cerba's previous major international acquisitions of Lifebrain (Italy) and Viroclinics-DDL (Netherlands), furthering the global expansion strategy initiated under EQT's majority ownership since 2021.

Gleamer raised €27 million in Series B funding to broaden its AI solution portfolio and accelerate global commercial development. The strategic plan involves expanding the software suite to include CT scans and mammography, aiming to cover 70% of radiologists' daily diagnostic needs. A significant portion of the capital is earmarked for strengthening commercial and technical teams in Europe and the United States, as well as deepening strategic partnerships with global medical imaging equipment manufacturers (OEMs).

Astorg has successfully completed the acquisition of OPEN Health from Amulet Capital Partners, executing a significant secondary buyout in the highly attractive healthcare services sector. Through this transaction, Astorg secures a controlling interest in a premier medical affairs and market access business, while the existing management team will continue to helm the organization. The strategic rationale for Astorg is deeply rooted in acquiring a highly scalable platform investment within the rapidly professionalizing medical communications space. As the pharmaceutical industry shifts toward complex, next-generation therapeutics, the demand for specialized, high-science communication and rigorous data analytics has transformed medical affairs from a supportive function into a central commercial driver. Astorg intends to deploy its substantial dry powder and leverage its extensive healthcare expertise to accelerate the company's next phase of growth, supporting both organic initiatives and highly targeted, value-accretive strategic acquisitions.

Kersia acquired 100% of Sopura from its shareholders as part of a strategic build-up program. This transaction was integrated into a larger financing package arranged during the acquirer's own ownership transition to a new private equity sponsor. The acquisition represents a major strategic shift, allowing the group to significantly increase its exposure to the beverage industry—moving from less than 2% to over 15% of its pro forma revenue. Strategically, the deal combines the target's specialized brewing hygiene expertise and rinse-free product lines with the acquirer's global food safety platform. Geographically, the operation provides the acquirer with immediate access to established manufacturing sites in Australia, South Africa, and Vietnam, while offering the target's products a pathway into North and South American markets through the group's existing network.

IK Investment Partners acquired a majority stake in Kersia from Ardian. This transaction was initiated through exclusive negotiations via the IK IX fund, marking the first deal for this specific vehicle. The investment strategy is focused on supporting the group through its next phase of growth and continuing an active global sector consolidation policy. The project builds on the target's remarkable trajectory, having tripled in size in less than four years through the successive integration of six specialized companies. The new shareholder intends to capitalize on the group's technological expertise and extensive geographical presence to reinforce its leadership in the food safety sector. The transaction also allows the historical shareholder to realize the value created while passing the baton to a partner experienced in supporting high-growth industrial leaders.